MEL sensitizes human hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating CaMKII-TAK1-JNK/p38 and inhibiting IκBαkinase-NFκB. The gene discussed is TNFSF10; the disease is hepatocellular carcinoma.